H.B. Fuller Company (FUL) slips despite deep earnings beat
H.B. Fuller Company (FUL) slipped after a mixed quarter that paired an adjusted EPS beat with a slight revenue miss. Our deep dive looks beyond the headline, covering margin expansion, segment trends, guidance, leverage, and why investors still see acquisition and execution risk.
H.B. Fuller Company (FUL) posted a mixed quarter, beating adjusted EPS expectations at $1.52 but missing revenue at $0.94 billion, and the stock fell 1.68% on the news. The results show improving margins, solid cash generation, and raised fiscal 2026 guidance, but investors are focusing on acquisition-related leverage and execution risk.
H.B. Fuller Company (FUL) slips after earnings beat
H.B. Fuller Company (FUL) delivered a mixed quarter, beating adjusted EPS estimates while falling short on revenue. The stock slips 1.68% to $50.21, with trading volume of 1.9 million shares versus a 753,107 average, as investors weigh stronger profits against acquisition and leverage risks.
Key Takeaways
Adjusted EPS reached $1.52, ahead of the $1.47 estimate, while revenue came in at $0.94B versus the $0.95B consensus.
EPS exceeded estimates in each of the five reported periods listed, including $1.41 in June 2026 and $1.28 in March 2026.
The latest detailed segment update showed BAS organic sales up 6% year over year, while Engineering Adhesives grew 5% excluding the exited solar business.
Fiscal 2026 guidance called for adjusted EPS of $4.60 to $4.90, EBITDA of $650 million to $675 million, and operating cash flow of $300 million to $325 million.
CEO Celeste Mastin emphasized pricing execution, supply continuity, restructuring savings, and medical adhesives as strategic priorities.
Analysts remain constructive overall, with nine Buy ratings and six Holds. Earlier target increases from JPMorgan, Citigroup, Deutsche Bank, and UBS support that view.
The headline FUL earnings result shows a clear split. Adjusted EPS of $1.52 beat the $1.47 estimate, but revenue of $0.94B missed the $0.95B consensus. That combination points to stronger earnings conversion rather than broad-based top-line acceleration.
EPS also reached the highest level in the five-period surprise history provided. The prior figures were $1.41 on June 24, $0.57 on March 25, $1.28 on January 14, and $1.26 on September 24, 2025. The company has therefore maintained a consistent record of beating the listed EPS estimates.
Revenue remains relatively stable across recent quarters. Reported quarterly revenue was $0.95B on May 30, $0.77B on February 28, $0.89B on November 29, $0.89B on August 30, and $0.90B on May 31. The latest $0.94B result sits near the upper end of that range, although it did not match the latest consensus.
The latest detailed profitability figures came from the second quarter. Revenue rose 5.8% year over year, while organic revenue increased 2.6%. Pricing contributed 3%, offsetting slightly lower volume. Adjusted EBITDA increased 9% to $181 million, and EBITDA margin expanded 70 basis points to 19.1%.
Adjusted gross margin reached 34.2%, up 200 basis points year over year. Pricing execution and restructuring savings drove the improvement. Adjusted SG&A rose 11%, although the increase was approximately 3% excluding foreign exchange and higher variable compensation tied to projected income.
Segment performance added useful detail. Hygiene, Health, and Consumable Adhesives delivered 3% organic growth, supported by medical, tape and label, and end-of-line packaging. Flexible packaging remained a drag, but the segment's EBITDA margin reached 17.9%, up 230 basis points.
Engineering Adhesives produced roughly 5% organic growth excluding solar, led by aerospace, electronics, and general industries. Including the solar exit, organic revenue declined 1%. Its EBITDA margin was 22.4%, while Building Adhesive Systems posted 6% organic sales growth and 10% EBITDA growth.
Cash generation also improved in the second quarter. Operating cash flow reached $121 million, described as a record second quarter, while net working capital fell to 16.4% of annualized revenue. Net debt to adjusted EBITDA declined to 3.1 times from 3.4 times a year earlier.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
FUL shares closed at $50.21, down from the prior close of $51.07. The 1.68% decline came with volume well above the average, a sign that the earnings result and the Advanced Medical Solutions transaction both drew active trading interest.
The muted stock response makes sense because the quarter contained both a profit beat and a revenue miss. The acquisition adds another layer. H.B. Fuller announced an all-cash offer of GBP 2.85 per AMS share, implying enterprise value of approximately GBP 715 million. Analyst commentary placed pro forma leverage near 4.0 times, up from 3.1 times before the deal.
Analyst sentiment remains positive but selective. The current consensus includes nine Buy ratings and six Holds, with no Sell ratings. JPMorgan upgraded FUL from Underweight to Neutral on May 27, then to Overweight on June 26 while raising its target from $58 to $67.
Citigroup raised its target from $70 to $75 on June 30 and kept a Buy rating. Deutsche Bank lifted its target from $70 to $72 on the same date, also retaining Buy. UBS raised its target from $63 to $71 on June 17 while maintaining Neutral.
Those target increases reflect confidence in pricing power and restructuring savings. However, the stock reaction shows that operating progress alone does not settle the investment case. Leverage, integration, and volume trends now carry greater weight in the valuation.
Management Commentary: Pricing, Supply, and Medical Growth
CEO Celeste Mastin framed the quarter around execution. Her comments focused on pricing, sourcing, and the Quantum Leap restructuring program. In plain English, H.B. Fuller is using its supply network and pricing actions to protect margins while competitors face disruption.
"We executed very well in the second quarter, delivering strong year-on-year revenue, EBITDA, and EPS growth, with results above the midpoint of our EBITDA guidance range." - Celeste Mastin, CEO, Earnings Call
Mastin also placed medical adhesives at the center of the long-term strategy. The AMS deal targets a market that H.B. Fuller describes as more resilient, more regulated, and more profitable than many traditional adhesive applications.
"Medical is a core strategic growth market for H.B. Fuller, given its durable demand trends, high regulatory-based entry barriers, and attractive margin profile." - Celeste Mastin, CEO, Earnings Call
The macro message was firm. Mastin said the company does not expect a rapid recovery in global supply chains after the Middle East disruption. She also said raw material costs will not fully return to pre-disruption levels, which keeps pricing discipline central to the margin outlook.
"We do not expect raw material costs to fully retrace to pre-disruption levels. The inflationary pressures introduced by this supply shock have reset the cost structure of our industry, and we are managing our business accordingly." - Celeste Mastin, CEO, Earnings Call
CFO John Corkrean supplied the financial framework. Fiscal 2026 guidance retained mid-single-digit net revenue growth and low-single-digit organic growth. Foreign exchange is expected to add 1% to 2% to revenue.
"Adjusted EBITDA for fiscal 2026 is now expected to be in the range of $650 million-$675 million. Adjusted EPS is now expected to be in the range of $4.60-$4.90, reflecting an increase in the midpoint of our full year guidance for both." - John Corkrean, CFO, Earnings Call
Corkrean also projected third-quarter EBITDA of $180 million to $190 million and operating cash flow of $300 million to $325 million for the full year. Those figures exclude the AMS transaction, so the guidance establishes an operating baseline before acquisition effects.
The H.B. Fuller Company earnings analysis comes down to earnings quality versus balance-sheet risk. Pricing, restructuring, and strong segment execution are lifting margins, while the AMS acquisition adds medical growth and a heavier leverage burden.
For now, the numbers support a constructive operating view: EPS beat estimates, EBITDA guidance rose, and analysts maintain a Buy-weighted consensus. The stock's decline shows that investors want proof that integration and deleveraging can match the pace of the company's strategic ambition.
+Did H.B. Fuller (FUL) beat earnings this quarter?
Yes. H.B. Fuller reported adjusted EPS of $1.52, above the $1.47 estimate, while revenue came in at $0.94 billion versus the $0.95 billion consensus. The company has also beaten the listed EPS estimate in each of the five reported periods shown.
+Why did H.B. Fuller stock fall after earnings?
FUL shares fell 1.68% to $50.21 because investors balanced the EPS beat against the revenue miss. Trading also reflected concern about the Advanced Medical Solutions acquisition and the potential increase in leverage.
+What is H.B. Fuller's fiscal 2026 guidance?
H.B. Fuller guided for adjusted EPS of $4.60 to $4.90, EBITDA of $650 million to $675 million, and operating cash flow of $300 million to $325 million. The outlook suggests continued earnings growth and strong cash generation despite near-term acquisition risk.
+How are analysts rating H.B. Fuller (FUL) after the report?
Analysts remain constructive, with nine Buy ratings and six Holds and no Sell ratings. Recent target increases from JPMorgan, Citigroup, Deutsche Bank, and UBS show confidence in pricing execution and restructuring savings.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on FUL?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
